[ET Net News Agency, 23 December 2024] CMB International raised the target price for
Hansoh Pharma (03692) to HKD25.24 from HKD24.11 and maintained the "buy" rating.
The research house said it believes that Hansoh has successfully developed a robust
pipeline of GLP-1 assets. The collaboration with MSD will accelerate the development of
HS-10535 and unlock global potential. (rc)